» Articles » PMID: 38469306

Abnormal Functional Lymphoid Tolerance and Enhanced Myeloid Exocytosis Are Characteristics of Resting and Stimulated PBMCs in Cystic Fibrosis Patients

Overview
Journal Front Immunol
Date 2024 Mar 12
PMID 38469306
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Cystic Fibrosis (CF) is the commonest genetically inherited disease (1 in 4,500 newborns) and 70% of people with CF (pwCF) harbour the F508Del mutation, resulting in misfolding and incorrect addressing of the channel CFTR to the epithelial membrane and subsequent dysregulation of fluid homeostasis. Although studies have underscored the importance and over-activation of myeloid cells, and in particular neutrophils in the lungs of people with CF (pwCF), relatively less emphasis has been put on the potential immunological bias in CF blood cells, at homeostasis or following stimulation/infection.

Methods: Here, we revisited, in an exhaustive fashion, in pwCF with mild disease (median age of 15, median % FEV1 predicted = 87), whether their PBMCs, unprimed or primed with a 'non specific' stimulus (PMA+ionomycin mix) and a 'specific' one (live =PAO1 strain), were differentially activated, compared to healthy controls (HC) PBMCs.

Results: 1) we analysed the lymphocytic and myeloid populations present in CF and Control PBMCs (T cells, NKT, Tgd, ILCs) and their production of the signature cytokines IFN-g, IL-13, IL-17, IL-22. 2) By q-PCR, ELISA and Luminex analysis we showed that CF PBMCs have increased background cytokines and mediators production and a partial functional tolerance phenotype, when restimulated. 3) we showed that CF PBMCs low-density neutrophils release higher levels of granule components (S100A8/A9, lactoferrin, MMP-3, MMP-7, MMP-8, MMP-9, NE), demonstrating enhanced exocytosis of potentially harmful mediators.

Discussion: In conclusion, we demonstrated that functional lymphoid tolerance and enhanced myeloid protease activity are key features of cystic fibrosis PBMCs.

Citing Articles

COVID-19 PBMCs are doubly harmful, through LDN-mediated lung epithelial damage and monocytic impaired responsiveness to live exposure.

Gaudin C, Born-Bony M, Villeret B, Jaillet M, Faille D, Timsit J Front Immunol. 2024; 15:1398369.

PMID: 38835759 PMC: 11148249. DOI: 10.3389/fimmu.2024.1398369.

References
1.
Margaroli C, Garratt L, Horati H, Dittrich A, Rosenow T, Montgomery S . Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2018; 199(7):873-881. PMC: 6444666. DOI: 10.1164/rccm.201803-0442OC. View

2.
Sly P, Gangell C, Chen L, Ware R, Ranganathan S, Mott L . Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013; 368(21):1963-70. DOI: 10.1056/NEJMoa1301725. View

3.
Cavinato L, Luly F, Pastore V, Chiappetta D, Sangiorgi G, Ferrara E . Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis. Eur Respir J. 2022; 61(4). PMC: 10066567. DOI: 10.1183/13993003.00725-2022. View

4.
Grover A, Sanseviero E, Timosenko E, Gabrilovich D . Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. Cancer Discov. 2021; 11(11):2693-2706. DOI: 10.1158/2159-8290.CD-21-0764. View

5.
Giacalone V, Giraldo D, Silva G, Hosten J, Peng L, Guglani L . Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells. Front Immunol. 2023; 14:1194253. PMC: 10551126. DOI: 10.3389/fimmu.2023.1194253. View